Clinical trial NCT01025479: Prevalence of Osteoporosis in Korean Prostate Cancer Patients Who is Receiving LHRH Agonist and/or Anti-androgen Agent
Official title: Prevalence of Osteoporosis in Korean Prostate Cancer Patients Who is Receiving LHRH Agonist and/or Anti-androgen Agent
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Prostate Cancer
Osteoporosis
Keywords: Osteoporosis
Prostate cancer
LHRH agonist and/or anti-androgen agent
Korean prostate cancer
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2009-12-03
Enrollment: 829
Sex: MALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Korean prostate cancer patients who are taking LHRH antagonist or anti- androgen or both of them within 6 months since starting.

Brief summary: Prevalence rate of osteoporosis and it's actual management condition in Prostate cancer patients who takes LHRH antagonist and anti androgen


Eligibility criteria: Inclusion Criteria:

* pathologic confirmation of prostate cancer
* patients who are taking LHRH antagonist or anti- androgen or both of them within 6 months since starting.

Exclusion Criteria:

* patients who are hard to be analysed by limitation of chart record according to investigators'discretion
* patients who already have been registered in this study

Primary outcomes:
measure: To define prevalence rate of osteoporosis in Prostate cancer patients who take LHRH antagonist or anti androgen (include MAB) at the stage of before treatment or it's initial stage.
Secondary outcomes:
measure: To assess whether proper osteoporosis prevention and treatment was given or not according to osteoporosis treatment guideline in prostate cancer patients who are enrolled in this study.
Other outcomes:
Locations:
city: Cheongju-si
country: Korea, Republic of
facility: Research Site
state: Chungcheongbuk-do
city: Chungju-si
country: Korea, Republic of
facility: Research Site
state: Chungcheongbuk-do
city: Cheonan-si
country: Korea, Republic of
facility: Research Site
state: Chungcheongnam-do
city: Gangneung-si
country: Korea, Republic of
facility: Research Site
state: Gangwon-do
city: Goyang-si
country: Korea, Republic of
facility: Research Site
state: Gyeonggi-do
city: Guri-si
country: Korea, Republic of
facility: Research Site
state: Gyeonggi-do
city: Gumi-si
country: Korea, Republic of
facility: Research Site
state: Gyeongsangbuk-do
city: Gyeongju-si
country: Korea, Republic of
facility: Research Site
state: Gyeongsangbuk-do
city: Masan-si
country: Korea, Republic of
facility: Research Site
state: Gyeongsangnam-do
city: Iksan-si
country: Korea, Republic of
facility: Research Site
state: Jeollabuk-do
city: Daegu
country: Korea, Republic of
facility: Research Site
city: Daejeon
country: Korea, Republic of
facility: Research Site
city: Gwangju
country: Korea, Republic of
facility: Research Site
city: Incheon
country: Korea, Republic of
facility: Research Site
city: Jeju
country: Korea, Republic of
facility: Research Site
city: Pusan
country: Korea, Republic of
facility: Research Site
city: Seoul
country: Korea, Republic of
facility: Research Site
city: Ulsan
country: Korea, Republic of
facility: Research Site
Study officials:
affiliation: AstraZeneca Korea
name: Joon Woo Bahn, MD
role: STUDY_DIRECTOR
References: